Trial · NCT03026556
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Stroke Overall (Hemorrhagic, Ischemic, Uncertain) | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed. In both cohorts, dabigatran patients were matched 1:1 to comparator patients based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| PRIMARY | Overall Major Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Ischemic Stroke | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Hemorrhagic Stroke | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Major Intracranial Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Major Extracranial Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Major GI Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Major Urogenital Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Major Other Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Upper GI Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | Lower GI Bleeding | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | TIA | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
| SECONDARY | All-cause Mortality | Baseline (July 1, 2010) until end of the observation period (June 30, 2016), 6 Years | Based on Department of Defense (DoD) outpatient prescription dispensed data the two separate study cohorts dabigatran vs rivaroxaban cohort and dabigatran vs apixaban cohort were formed and matched 1: 1 based on their baseline characteristics using the propensity score matching (PSM). | Event Rate in 100 person-years | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03026556/outcomes